Quality by design - implications for drug development and manufacture
- In: D18 - Good Manufacturing Practices - Expectations for the coming decade (part II) on Thursday, 8 September 2011, 14:00-17:00
- At: Hyderabad (India) (2011)
- Type: Presentation
- By: SAM, Tom (MSD, Oss, Netherlands)
The introduction of Quality by Design has transformed in the past 5 years the way we think about drug development and manufacture to an extent that we even speak about a paradigm shift. We now all know that drugs should be developed science and risk based rather than by traditional approaches. Be it true in theory, in practice still many companies.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019